National pharmaceuticals pricing authority asked pharmaceutical industries to reduce prices of anticancer medicines post declining custom duty to zero. The government reduced custom duty on three Anti-cancer medicines namely, Trastuzumab Deruxtecan, Osimertinib and Durvalumab.

Glioblastoma is the most common kind of malignant brain tumor in adults. So far, no treatment has been able to make this aggressive tumor permanently disappear. The tumor cells are too varied, and the microenvironment is too tumor-friendly. Researchers at the University of Basel and University Hospital Basel have now developed an immunotherapy that not only attacks the tumor—it also turns its microenvironment against it.